Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)
| Fund Assets | 1.02B |
| Expense Ratio | 0.80% |
| Min. Investment | $1,000 |
| Turnover | 21.87% |
| Dividend (ttm) | 18.23 |
| Dividend Yield | 10.28% |
| Dividend Growth | 55.01% |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 22, 2025 |
| Previous Close | 177.41 |
| YTD Return | -1.93% |
| 1-Year Return | 45.14% |
| 5-Year Return | 24.99% |
| 52-Week Low | 94.80 |
| 52-Week High | 182.20 |
| Beta (5Y) | n/a |
| Holdings | 89 |
| Inception Date | Sep 1, 2009 |
About FTDZX
Franklin Biotechnology Discovery Fund Advisor Class is a mutual fund that focuses on delivering capital appreciation by investing primarily in the biotechnology sector. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms—enterprises that derive a significant portion of their revenue from biotechnology-related activities. The fund’s portfolio often includes both established and emerging biotechnology firms, with a notable allocation to smaller capitalization companies, typically those with market values below $2 billion at the time of investment. While the fund maintains a majority exposure to U.S.-based companies, it may allocate up to 20% of its assets to foreign securities, including American, European, and Global Depositary Receipts. Managed using a fundamental, research-driven investment approach, the fund seeks out companies with identifiable drivers of future earnings growth and sustainable growth characteristics. Franklin Biotechnology Discovery Fund Advisor Class plays a significant role in offering investors a specialized vehicle for gaining exposure to innovations and growth opportunities within the global biotechnology industry, reflecting both the sector’s risk profile and potential for long-term growth.
Performance
FTDZX had a total return of 45.14% in the past year, including dividends. Since the fund's inception, the average annual return has been 18.00%.
Top 10 Holdings
40.13% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 5.31% |
| Jazz Pharmaceuticals plc | JAZZ | 4.70% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.60% |
| Amgen Inc. | AMGN | 4.58% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.52% |
| argenx SE | ARGX | 4.02% |
| Praxis Precision Medicines, Inc. | PRAX | 3.32% |
| Insmed Incorporated | INSM | 3.20% |
| Terns Pharmaceuticals, Inc. | TERN | 3.04% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.85% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $18.2306 | Dec 22, 2025 |
| Dec 20, 2024 | $11.7607 | Dec 20, 2024 |
| Dec 20, 2022 | $0.4163 | Dec 20, 2022 |
| Dec 15, 2021 | $18.0843 | Dec 15, 2021 |
| Dec 15, 2020 | $10.3921 | Dec 15, 2020 |
| Dec 16, 2019 | $14.1643 | Dec 18, 2019 |